AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06663293
Drug: midazolam, ketamine, propofol
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sedation was done with IV midazolam 0.025 to 0.1 mg/kg, IV ketamine 0.25 to 0.5 mg/kg, and IV propofol (1%) 0.25 to 0.5 mg/kg
Trial: NCT06663293
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sedation maintenance was done by propofol 0.5 to 1 mg/kg/h
Trial: NCT05785767
Drug: fianlimab
RxNorm normalized name: Fianlimab
DrugBank: Fianlimab (DB18858)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every three weeks (Q3W) as intravenous (IV) co-infusion
Trial: NCT05785767
Drug: cemiplimab
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Q3W as IV co-infusion
Trial: NCT06695585
Drug: Lidocaine 2% without vessel constrictor
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: different volumes of intravesical 2% lidocaine without epinephrine, all patients will be receiving bladder botox but this will not be compared
Trial: NCT06685796
Drug: BEBT-209 capsules
RxNorm normalized name: bebtelovimab
DrugBank: Bebtelovimab (DB16755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEBT-209 Capsules, dosage: 150mg, frequency and duration of administration: administered on days 1, 2, 8, and 9 of each cycle, with a 21-day cycle. On days 1 and 8, take orally once before dinner or twice (before breakfast and before dinner), and on days 2 and 9, take orally once before breakfast.
Trial: NCT06685796
Drug: Carboplatin injection
RxNorm normalized name: Carboplatin Injection
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin injection, dosage: AUC 2 × (creatinine clearance rate + 25), frequency and duration of administration: administered on days 1 and 8 or days 2 and 9 of each cycle, with a 21-day cycle.
Trial: NCT06685796
Drug: Gemcitabine hydrochloride for injection
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine hydrochloride for injection, dosage: 1000mg/m², frequency and duration of administration: administered on days 1 and 8 or days 2 and 9 of each cycle, with a 21-day cycle.
Trial: NCT05103735
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: awake neurosurgery under propofol-remifentanil sedation
Trial: NCT06023368
Drug: EMLA Cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cream applied around the port prior to access
Trial: NCT05918302
Drug: 177Lu-edotreotide
RxNorm normalized name: edotreotride
DrugBank: Edotreotide (DB17969)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 cycles of 7.5 ± 0.7 Giga becquerel (GBq) 177Lu-edotreotide
Trial: NCT05918302
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg orally once daily (QD)
Trial: NCT05080543
Drug: Albumin 20% and terlipressin
DrugBank: Terlipressin (DB02638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluation the effect of adding 20% HSA and terlipressin on microvascular ﬂow index (MFI), flow heterogeneity index, total vessel density (TVD), and perfused vessel density (PVD) in comparison to the standard care in patient with septic shock.
Trial: NCT06081348
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral capsule (25mg, 50mg, 100mg, 200mg)
Trial: NCT04885712
Drug: Metformin≥1000mg
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects take the investigational products once a day for 24 weeks.
Trial: NCT04885712
Drug: Pioglitazone 15mg
RxNorm normalized name: METFORMIN 500MG/PIOGLITAZONE 15MG TAB
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects take the investigational products once a day for 24 weeks.
Trial: NCT04885712
Drug: Pioglitazone 30 mg
RxNorm normalized name: pioglitazone 30 MG
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects take the investigational products once a day for 24 weeks.
Trial: NCT04885712
Drug: Pioglitazone 15mg Placebo
RxNorm normalized name: pioglitazone 15 MG
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects take the investigational products once a day for 24 weeks.
Trial: NCT04885712
Drug: Pioglitazone 30mg Placebo
RxNorm normalized name: pioglitazone 30 MG
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects take the investigational products once a day for 24 weeks.
Trial: NCT04885712
Drug: Dapagliflozin 10mg
RxNorm normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects take the investigational products once a day for 24 weeks.
Trial: NCT05574400
Drug: Dextrose Water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose 5% in water
Trial: NCT05540600
Drug: Digoxin 0.25 mg
RxNorm normalized name: digoxin 0.25 MG
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will have the dose of one tablet of 0.25mg per day
Trial: NCT05540600
Drug: Bisoprolol
RxNorm normalized name: Bisoprolol
DrugBank: Bisoprolol (DB00612)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will have the dose of bisoprolol 2.5 mg or 5 mg twice a day based on the arterial pressure at randomization
Trial: NCT04814433
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FDA-approved usage for intravenous tranexamic acid (TXA) is for heavy menstrual bleeding and short-term prevention in patients with hemophilia.~Total dose of 500 mg (20 mL) total will be given.
Trial: NCT04814433
Drug: Aminocaproic acid
RxNorm normalized name: Aminocaproic Acid
DrugBank: Aminocaproic acid (DB00513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FDA notes that aminocaproic acid is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. Aminocaproic acid inhibits both the action of plasminogen activators and to a lesser degree, plasmin activity. The fibrinolysis-inhibitory effects of aminocaproic acid appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.~Total of 1000 mg total will be given.
Trial: NCT05100017
Drug: Methocarbamol
RxNorm normalized name: Methocarbamol
DrugBank: Methocarbamol (DB00423)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive oral Methocarbamol 750mg every six hours as needed for pain post ureteroscopy in addition to the standard postoperative pain regimen.
Trial: NCT05100017
Drug: Oxybutynin
RxNorm normalized name: Oxybutynin
DrugBank: Oxybutynin (DB01062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive oral Oxybutynin XL 10mg daily for pain post ureteroscopy in addition to the standard postoperative pain regimen.
Trial: NCT04744129
Drug: NN414
RxNorm normalized name: Alogliptin
DrugBank: Alogliptin (DB06203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To investigate the role of NN414 on cerebral hemodynamic in migraine patients
Trial: NCT04744129
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To investigate the role of NN414 compared with saline cerebral hemodynamic in migraine patients.
Trial: NCT04814433
Drug: Recombinant Human Thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical thrombin is FDA approved as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques is not sufficient.~Recombinant human thrombin is available as 5000-unit and 20,000-unit vials of sterile recombinant topical thrombin lyophilized powder for solution. When reconstituted as directed, the final solution contains 1000 units/mL.~For topical application, a total of 10000 units per open surgical study arm involving use of Thrombin will be given
Trial: NCT03025867
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT05532163
Drug: Natalizumab
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT04891861
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Direct Oral Anticoagulation all at label dose and frequency
Trial: NCT05737693
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Week-long exposure therapy with ketamine infusion on day 2 and 4 of the psychotherapy
Trial: NCT05737693
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Week-long exposure therapy with midazolam infusion on day 2 and 4 of the psychotherapy
Trial: NCT05199038
Drug: Octreotide
RxNorm normalized name: Octreotide
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Octreotide infusion for 2 days in patients with bleeding esophageal varices.
Trial: NCT04389671
Drug: Lucinactant
RxNorm normalized name: Lucinactant
DrugBank: Lucinactant (DB04897)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lucinactant administered as a liquid at a dose of 80 mg total phospholipids (TPL)/kg lean body weight delivered
Trial: NCT05365464
Drug: Progesterone Pill
RxNorm normalized name: progesterone Pill
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Orally active progesterone
Trial: NCT05365464
Drug: hCG
RxNorm normalized name: HCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by subcutaneous injection
Trial: NCT05812677
Drug: Recombinant oncolytic herpes simplex virus type Ⅰ (R130)
RxNorm normalized name: Dna (recombinant herpes simplex virus type 1 strain kos plasmid vector kb103 human collagen col7a1-specifying)
DrugBank: Tipapkinogene sovacivec (DB06239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
Trial: NCT05061134
Drug: Ceralasertib
RxNorm normalized name: Ceralasertib
DrugBank: Ceralasertib (DB14917)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceralasertib (240 mg) will be administered orally twice daily.
Trial: NCT05726630
Drug: Divozilimab
RxNorm normalized name: divozilimab
DrugBank: Divozilimab (DB18878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti CD20 monoclonal antibody
Trial: NCT05431179
Drug: Zilovertamab
RxNorm normalized name: Zilovertamab
DrugBank: Zilovertamab (DB18403)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After 16 weeks in the open-label Ibrutinib phase, participants will receive zilovertamab (600mg) administered by IV every 2 weeks for 3 administrations and then every 4 weeks thereafter.
Trial: NCT05431179
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All participants will receive oral Ibrutinib (560mg) daily.
Trial: NCT04616235
Drug: Tocilizumab Injectable Product
RxNorm normalized name: tocilizumab Injectable Product
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The intervention group will undergo intense aerobic exercise with prior IL-6R infusion for 1h prior to the exercise bout.
Trial: NCT06427174
Drug: Fascia iliaca block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For the group who will receive the fascia iliaca block .... After induction of the general anesthesia and before skin incision, fascia iliaca block will be performed in the patient while he is in the supine position
Trial: NCT06427174
Drug: Caudal block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: second group will receive the caudal block, we use bupivacaine 0.5 mg / kg.
Trial: NCT05052307
Drug: CoronaVac COVID-19 vaccine
RxNorm normalized name: COVID-19 VACCINE ADENOVIRUS-26
DrugBank: AVAC (DB05441)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoronaVac COVID-19 vaccine
Trial: NCT04814433
Drug: Bupivacaine Hydrochloride with Epinephrine
RxNorm normalized name: bupivacaine hydrochloride / epinephrine Cartridge [Marcaine with Epinephrine]
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical bupivacaine is FDA approved as indicated for the production of local anesthesia for procedures by infiltration injection. It is frequently used as a standard local anesthetic for surgical procedures.~Each mL contains bupivacaine hydrochloride and 0.005 mg epinephrine, with 0.5 mg sodium metabisulfite as an antioxidant and 0.2 mg citric acid (anhydrous) as stabilizer.~Total of 5 mLs per open surgical study arm involving Bupivacaine Hydrochloride with Epinephrine will be given
Trial: NCT06230055
Drug: Systematic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic chemotherapy: including capecitabine(1000mg/m2 bid, d1-14, q3w, po), gemcitabine(1000mg/m2, d1,8, q3w, ivgtt), vinorelbine(25mg/m2, d1,8, q3w, ivgtt), docetaxel(75mg/m2, d1, q3w, ivgtt),Nab-paclitaxel(125mg/m2, d1,8, q3w, ivgtt), or iribrin(1.4mg/m2, d1,8, q3w, iv).
Trial: NCT05111769
Drug: Recombinant human brain natriuretic peptide
RxNorm normalized name: Brain natriuretic peptide
DrugBank: .gamma.-brain natriuretic peptide (DB19026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. To determine the effect of rhBNP on hemodynamics in sepsis based on PiCCO hemodynamic monitoring; 2. To collect and sort out the relevant data to determine the effects of rhBNP on cardiac function and kidney function, including cardiac ultrasound, kidney blood flow index and related laboratory tests. 3. To determine the effect of rhBNP on the final prognosis of patients, including ICU mortality and hospital mortality, ICU time, hospital stay, ventilator use time, kidney replacement therapy time, vasoactive drug dosage and time.
Trial: NCT05630612
Drug: Sparsentan
RxNorm normalized name: SPARSENTAN
DrugBank: Sparsentan (DB12548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 weeks of treatment with sparsentan or irbesartan. This will be administered in a double-blind fashion.
Trial: NCT06140238
Drug: Parecoxib
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Parecoxib administration 15 minutes before start surgical operation
Trial: NCT05656573
Drug: CART-PSMA cells
RxNorm normalized name: Gallium-68 PSMA
DrugBank: Gallium-68 PSMA (DB16303)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study consists of 2 parts:~Part A (Dose Escalation): The investigators are looking the highest dose of the study intervention that can be administered safely without severe or unmanageable side effects in participants that advanced prostate cancer.~Part B (Expansion Cohort): Participants will be treated at the respective dose (at or below the Maximum Tolerated Dose), as determined during Part A (Dose Escalation).~Up to 4 dosing cohorts, with up to 3 subjects enrolled in each cohort, will be explored as follows:~Cohort 1： CART-PSMA cells 1-3x10\^7/M\^2 (body surface area); Cohort 2： CART-PSMA cells 1-3x10\^8/M\^2 (body surface area); Cohort 3： Lymphodepletion chemotherapy + CART-PSMA cells 1-3x10\^7/M\^2 (body surface area); Cohort 4： Lymphodepletion chemotherapy + CART-PSMA cells 1-3x10\^8/M\^2 (body surface area).
Trial: NCT04438512
Drug: Midomafetamine
RxNorm normalized name: Midomafetamine
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of 80 or 120 mg midomafetamine HCl in combination with manualized therapy and a supplemental dose 1.5 to 2 hrs later of 40 or 60 mg midomafetamine HCl, respectively
Trial: NCT05343429
Drug: Benzydamine hydrochloride
RxNorm normalized name: benzydamine hydrochloride
DrugBank: Benzydamine (DB09084)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In BN group,15 ml of 0.15 % Benzydamine hydrochloride (BN) will be dissolved in 15 ml plain water in a sterile container and given to participants before anesthesia for surgery
Trial: NCT05343429
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In group AP, Aspirin (AP) 600 mg Aspirin tablets dissolved in 30 ml of plain water in a sterile container will be given to participants for gargling before anesthesia for surgery
Trial: NCT06214481
Drug: Rocatinlimab
RxNorm normalized name: Rocatinlimab
DrugBank: Rocatinlimab (DB18809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT05966194
Drug: RRx-001
RxNorm normalized name: RRx-001
DrugBank: RRx-001 (DB12060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRx-001 for injection (4 mg or 8 mg)
Trial: NCT05966194
Drug: Cisplatin for injection 100 mg/m2
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin for injection 100 mg/m2
Trial: NCT06222294
Drug: Remimazolam Tosilate
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Loading dose: 0.08mg/kg Maintenance dose: IV remimazolam tosilate, dose range 0-2.0mg/kg/h, increment or decrement of 0.1-0.2mg/kg/h
Trial: NCT06222294
Drug: Propofol Medium and Long Chain Fat Emulsion Injection
RxNorm normalized name: propofol lipid emulsion
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loading dose: 0.3-0.5mg/kg Maintenance dose: IV Propofol Medium and Long Chain Fat Emulsion Injection, dose range 0.3-4.0mg/kg/h, increment or decrement of 0.3-0.6mg/kg/h
Trial: NCT05994534
Drug: N-Acetylcysteine Amide
DrugBank: Acetylcysteine amide (DB14480)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, oral solution
Trial: NCT00002316
Drug: Lobradimil
RxNorm normalized name: Labradimil
DrugBank: Labradimil (DB06549)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002316
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05171335
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive approximately six, 28-day cycles of lenvatinib (LENVIMA®, Eisai Inc., Woodcliff Lake, NJ). Lenvatinib will be administered at 12 mg orally once daily for patients with a body weight ≥60 kg and at 8 mg orally once daily for patients with a body weight of \<60 kg.~Administration of lenvatinib will occur at least 2 weeks before the first standard of care TACE procedure and study drug treatment will continue for 6 months. Lenvatinib will be held for 7 days before and 7 days after each TACE. Participants can receive up to 3 TACE procedures per protocol depending on their response and transplantation time.
Trial: NCT06218784
Drug: iN1011-N17 HCl Suspension (Part 1)
RxNorm normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose: 100 mg b.i.d for 7 days (Multiple Ascending Dose)
Trial: NCT06218784
Drug: iN1011-N17 HCl Capsule (Part 1)
RxNorm normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose: 200, 400, 800 mg b.i.d for 7 days (Multiple Ascending Dose)
Trial: NCT06218784
Drug: iN1011-N17 HCl Capsule (Part 2)
RxNorm normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose: 400 mg QD
Trial: NCT06218784
Drug: iN1011-N17 Mesylate Capsule (Part 2)
RxNorm normalized name: Ergoloid Mesylates Capsules
DrugBank: Ergoloid mesylate (DB01049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose: 400 mg QD
Trial: NCT06218784
Drug: iN1011-N17 HCl Capsule (Part 3)
RxNorm normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose: 400 mg b.i.d for 14 days
Trial: NCT06218784
Drug: iN1011-N17 Mesylate Capsule (Part 3)
RxNorm normalized name: Ergoloid Mesylates Capsules
DrugBank: Ergoloid mesylate (DB01049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose: 400 mg b.i.d for 14 days
Trial: NCT04880889
Drug: BL 3000
RxNorm normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule 500 mg
Trial: NCT06092957
Drug: Cisplatin-based induction chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based induction chemotherapy will be given every 3 weeks for 3 cycles before radiotherapy including GP, TP, and TPF regimen.
Trial: NCT06092957
Drug: Concurrent Chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 100mg/m2 every 3 weeks for 2 cycles
Trial: NCT05172310
Drug: 68Ga-FAPI-46
RxNorm normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * \[68Ga\] Ga-FAPI-46 Solution for Injection is manufactured at the Karolinska University Hospital Radiopharmacy facilities, for imaging studies with Positron Emission Tomography (PET).~* It is a radiolabelled Fibroblast Activation Protein Inhibitor (FAPI) used for PET of a number of different cancer entities.~* Depending on the labelling yield 50 - 370 megabecquerel (MBq) of \[68Ga\] Ga-FAPI-46 Solution for Injection will be administered intravenously 60 minutes prior to whole-body PET image acquisition.
Trial: NCT00000778
Drug: Isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000778
Drug: Levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04739774
Drug: CHF6001 DPI
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single dose of CHF6001